(Q34569008)

3 August 2017

1 reference

title

Oxaliplatin: a review of evolving concepts (English)

1 reference

3 August 2017

1 reference

Sridhar Mani

1

1 reference

3 August 2017

Martin A Graham

2

1 reference

3 August 2017

David B Bregman

3

1 reference

3 August 2017

Percy Ivy

4

1 reference

3 August 2017

Stephen G Chaney

5

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

20

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

246-263

1 reference

Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Excision Repair in Mammalian Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Displacement of the bidentate malonate ligand from (d,l-trans-1,2-diaminocyclohexane)malonatoplatinum(II)by physiologically important compounds in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Cisplatin- and carboplatin-DNA adducts: is Pt-AG the cytotoxic lesion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Antitumour activity of oxaliplatin in neuroblastoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Antitumor activity of l-OHP in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin: pharmacokinetics and chronopharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Ongoing and unsaid on oxaliplatin: the hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Allergic reactions to cytotoxic drugs--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

DNA adducts from chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Molecular mechanism of nucleotide excision repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Nucleotide excision repair in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

The DNA damage-recognition problem in human and other eukaryotic cells: the XPA damage binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

21 January 2018

Life without DNA repair

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

HER-2/neu signal transduction in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

A novel function of emodin: enhancement of the nucleotide excision repair of UV- and cisplatin-induced DNA damage in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Nickel(II) increases the sensitivity of V79 Chinese hamster cells towards cisplatin and transplatin by interference with distinct steps of DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Kinetics of the reaction of cis-platinum compounds with DNA in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

High-performance liquid chromatographic separation of platinum complexes containing the cis-1,2-diaminocyclohexane carrier ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Biotransformations of oxaliplatin in rat blood in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Intracellular glutathione and cytotoxicity of platinum complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Phase I study of oxaliplatin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Anaphylactic reaction to oxaliplatin: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin-induced haemolytic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Anaphylaxis after oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Severe anaphylactic reactions to oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Base excision repair of oxidative DNA damage activated by XPG protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001152

21 January 2018

Identifiers

DOI

10.1081/CNV-120001152

1 reference

3 August 2017

1 reference